Mesenchymal stem cells in lung cancer tumor microenvironment: Their biological properties, influence on tumor growth and therapeutic implications

Cancer Letters

Volumn 353, Issue 2, 2014, Pages 145-152

  Liu, Renwang ^a   Wei, Sen ^a   Chen, Jun ^a   Xu, Song ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Lung cancer; Mesenchymal stem cells; Microenvironment

Indexed keywords

CONDITIONALLY REPLICATING ADENOVIRUS; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; INTERLEUKIN 24; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMA ASSOCIATED FIBROBLAST; CELL DIFFERENTIATION; CELL HOMING; DISTANT METASTASIS; DRUG EFFICACY; FIBROBLAST; GENETIC TRANSFECTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG FIBROSIS; LUNG METASTASIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR INTERACTION; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; RADIATION PNEUMONIA; SHORT SURVEY; STEM CELL GENE THERAPY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; CANCER STEM CELL; CELL PROLIFERATION; LUNG TUMOR; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; RADIATION INJURY; REVIEW;

LUNG CANCER; MESENCHYMAL STEM CELLS; MICROENVIRONMENT;

ANIMALS; CELL PROLIFERATION; HUMANS; LUNG NEOPLASMS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION INJURIES; TUMOR MICROENVIRONMENT;

EID: 84908700491     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.047     Document Type: Review

References (59)

1. Klaus M., Stavroulaki E., Kastrinaki M.C., Fragioudaki P., Giannikou K., Psyllaki M., et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev 2010, 19:1043-1054.
2. Zhao Z.G., Xu W., Yu H.P., Fang B.L., Wu S.H., Li F., et al. Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes. Cancer Lett 2012, 317:136-143.
3. Arnulf B., Lecourt S., Soulier J., Ternaux B., Lacassagne M.N., Crinquette A., et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007, 21:158-163.
4. Xu S., Evans H., Buckle C., De Veirman K., Hu J., Xu D., et al. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia 2012, 26:2546-2549.
5. Gottschling S., Granzow M., Kuner R., Jauch A., Herpel E., Xu E.C., et al. Mesenchymal stem cells in non-small cell lung cancer - different from others? Insights from comparative molecular and functional analyses. Lung Cancer 2013, 80:19-29.
6. Fernandez Vallone V.B., Hofer E.L., Choi H., Bordenave R.H., Batagelj E., Feldman L., et al. Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis. Clin. Exp. Metastasis 2013, 30:317-332.
7. Hofer E.L., La Russa V., Honegger A.E., Bullorsky E.O., Bordenave R.H., Chasseing N.A. Alteration on the expression of IL-1, PDGF, TGF-beta, EGF, and FGF receptors and c-Fos and c-Myc proteins in bone marrow mesenchymal stroma cells from advanced untreated lung and breast cancer patients. Stem Cells Dev 2005, 14:587-594.
8. Xu S., Cecilia Santini G., De Veirman K., Vande Broek I., Leleu X., De Becker A., et al. Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS ONE 2013, 8:e79752.
9. Zhang M.H., Hu Y.D., Xu Y., Xiao Y., Luo Y., Song Z.C., et al. Human mesenchymal stem cells enhance autophagy of lung carcinoma cells against apoptosis during serum deprivation. Int. J. Oncol 2013, 42:1390-1398.
10. Suzuki K., Sun R., Origuchi M., Kanehira M., Takahata T., Itoh J., et al. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol. Med 2011, 17:579-587.
11. Block G.J., Ohkouchi S., Fung F., Frenkel J., Gregory C., Pochampally R., et al. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 2009, 27:670-681.
12. Ohkouchi S., Block G.J., Katsha A.M., Kanehira M., Ebina M., Kikuchi T., et al. Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. Mol. Ther 2012, 20:417-423.
13. Zhang Y., Daquinag A., Traktuev D.O., Amaya-Manzanares F., Simmons P.J., March K.L., et al. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 2009, 69:5259-5266.
14. Jeon E.S., Lee I.H., Heo S.C., Shin S.H., Choi Y.J., Park J.H., et al. Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptor-dependent mechanism. Biochim. Biophys. Acta 2010, 1801:1205-1213.
15. Tian L.L., Yue W., Zhu F., Li S., Li W. Human mesenchymal stem cells play a dual role on tumor cell growth in vitro and in vivo. J. Cell. Physiol 2011, 226:1860-1867.
16. Li L., Tian H., Chen Z., Yue W., Li S., Li W. Inhibition of lung cancer cell proliferation mediated by human mesenchymal stem cells. Acta Biochim. Biophys. Sin. (Shanghai) 2011, 43:143-148.
17. Keramidas M., de Fraipont F., Karageorgis A., Moisan A., Persoons V., Richard M.J., et al. The dual effect of MSCs on tumour growth and tumour angiogenesis. Stem Cell Res. Ther 2013, 4:41.
18. Bremnes R.M., Donnem T., Al-Saad S., Al-Shibli K., Andersen S., Sirera R., et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol 2011, 6:209-217.
19. Do E.K., Kim Y.M., Heo S.C., Kwon Y.W., Shin S.H., Suh D.S., et al. Lysophosphatidic acid-induced ADAM12 expression mediates human adipose tissue-derived mesenchymal stem cell-stimulated tumor growth. Int. J. Biochem. Cell Biol 2012, 44:2069-2076.
20. Jacobsen J., Wewer U.M. Targeting ADAM12 in human disease: head, body or tail?. Curr. Pharm. Des 2009, 15:2300-2310.
21. Mino N., Miyahara R., Nakayama E., Takahashi T., Takahashi A., Iwakiri S., et al. A disintegrin and metalloprotease 12 (ADAM12) is a prognostic factor in resected pathological stage I lung adenocarcinoma. J. Surg. Oncol 2009, 100:267-272.
22. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer 2003, 3:582-591.
23. Jeon E.S., Moon H.J., Lee M.J., Song H.Y., Kim Y.M., Cho M., et al. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells 2008, 26:789-797.
24. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9:274-284.
25. Valastyan S., Weinberg R.A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147:275-292.
26. Xu M.H., Gao X., Luo D., Zhou X.D., Xiong W., Liu G.X. EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. PLoS ONE 2014, 9:e87893.
27. Choe C., Shin Y.S., Kim S.H., Jeon M.J., Choi S.J., Lee J., et al. Tumor-stromal interactions with direct cell contacts enhance motility of non-small cell lung cancer cells through the hedgehog signaling pathway. Anticancer Res 2013, 33:3715-3723.
28. Guan J., Chen J. Mesenchymal stem cells in the tumor microenvironment. Biomed. Rep 2013, 1:517-521.
29. Konopleva M., Konoplev S., Hu W., Zaritskey A.Y., Afanasiev B.V., Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002, 16:1713-1724.
30. Bergfeld S.A., Blavier L., Declerck Y.A. Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol. Cancer Ther 2014.
31. Roodhart J.M., Daenen L.G., Stigter E.C., Prins H.J., Gerrits J., Houthuijzen J.M., et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011, 20:370-383.
32. Mink S.R., Vashistha S., Zhang W., Hodge A., Agus D.B., Jain A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol. Cancer Res 2010, 8:809-820.
33. Zhang X., Zhang L., Xu W., Qian H., Ye S., Zhu W., et al. Experimental therapy for lung cancer: umbilical cord-derived mesenchymal stem cell-mediated interleukin-24 delivery. Curr. Cancer Drug Targets 2013, 13:92-102.
34. Stoff-Khalili M.A., Rivera A.A., Mathis J.M., Banerjee N.S., Moon A.S., Hess A., et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res. Treat 2007, 105:157-167.
35. Chen Q., Cheng P., Yin T., He H., Yang L., Wei Y., et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma. Int. J. Mol. Med 2012, 30:527-534.
36. Hakkarainen T., Sarkioja M., Lehenkari P., Miettinen S., Ylikomi T., Suuronen R., et al. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum. Gene Ther 2007, 18:627-641.
37. Wei H.J., Wu A.T., Hsu C.H., Lin Y.P., Cheng W.F., Su C.H., et al. The development of a novel cancer immunotherapeutic platform usingtumor-targeting mesenchymal stem cells and a protein vaccine. Mol. Ther 2011, 19:2249-2257.
38. Kanehira M., Xin H., Hoshino K., Maemondo M., Mizuguchi H., Hayakawa T., et al. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 2007, 14:894-903.
39. Xin H., Kanehira M., Mizuguchi H., Hayakawa T., Kikuchi T., Nukiwa T., et al. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007, 25:1618-1626.
40. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
41. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997, 16:5386-5397.
42. Kruyt F.A. TRAIL and cancer therapy. Cancer Lett 2008, 263:14-25.
43. Allen J.E., El-Deiry W.S. Regulation of the human TRAIL gene. Cancer Biol. Ther 2012, 13:1143-1151.
44. Lee R.H., Yoon N., Reneau J.C., Prockop D.J. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. Cell Stem Cell 2012, 11:825-835.
45. Reagan M.R., Seib F.P., McMillin D.W., Sage E.K., Mitsiades C.S., Janes S.M., et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J. Breast Cancer 2012, 15:273-282.
46. Mohr A., Lyons M., Deedigan L., Harte T., Shaw G., Howard L., et al. Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model. J. Cell. Mol. Med 2008, 12:2628-2643.
47. Hu Y.L., Huang B., Zhang T.Y., Miao P.H., Tang G.P., Tabata Y., et al. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection. Mol. Pharm 2012, 9:2698-2709.
48. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 2009, 69:4134-4142.
49. Ren C., Kumar S., Chanda D., Chen J., Mountz J.D., Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells 2008, 26:2332-2338.
50. Matsuzuka T., Rachakatla R.S., Doi C., Maurya D.K., Ohta N., Kawabata A., et al. Human umbilical cord matrix-derived stem cells expressing interferon-beta gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice. Lung Cancer 2010, 70:28-36.
51. Seo S.H., Kim K.S., Park S.H., Suh Y.S., Kim S.J., Jeun S.S., et al. The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 2011, 18:488-495.
52. Cappuccini F., Eldh T., Bruder D., Gereke M., Jastrow H., Schulze-Osthoff K., et al. New insights into the molecular pathology of radiation-induced pneumopathy. Radiother. Oncol 2011, 101:86-92.
53. Mouiseddine M., Francois S., Semont A., Sache A., Allenet B., Mathieu N., et al. Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br. J. Radiol 2007, 80:S49-S55. Spec No 1.
54. Xue J., Li X., Lu Y., Gan L., Zhou L., Wang Y., et al. Gene-modified mesenchymal stem cells protect against radiation-induced lung injury. Mol. Ther 2013, 21:456-465.
55. Kursova L.V., Konoplyannikov A.G., Pasov V.V., Ivanova I.N., Poluektova M.V., Konoplyannikova O.A. Possibilities for the use of autologous mesenchymal stem cells in the therapy of radiation-induced lung injuries. Bull. Exp. Biol. Med 2009, 147:542-546.
56. Montemurro T., Andriolo G., Montelatici E., Weissmann G., Crisan M., Colnaghi M.R., et al. Differentiation and migration properties of human foetal umbilical cord perivascular cells: potential for lung repair. J. Cell. Mol. Med 2011, 15:796-808.
57. Ortiz L.A., Gambelli F., McBride C., Gaupp D., Baddoo M., Kaminski N., et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc. Natl Acad. Sci. U.S.A. 2003, 100:8407-8411.
58. Di G.H., Jiang S., Li F.Q., Sun J.Z., Wu C.T., Hu X., et al. Human umbilical cord mesenchymal stromal cells mitigate chemotherapy-associated tissue injury in a pre-clinical mouse model. Cytotherapy 2012, 14:412-422.
59. Dai L.J., Moniri M.R., Zeng Z.R., Zhou J.X., Rayat J., Warnock G.L. Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett 2011, 305:8-20.